Free shipping on all orders over $ 500

A-1331852

Cat. No. M7548

All AbMole products are for research use only, cannot be used for human consumption.

A-1331852  Structure
Synonym:

A1331852

Size Price Availability Quantity
10mM*1mL in DMSO USD 172  USD172 In stock
5mg USD 122  USD122 In stock
10mg USD 192  USD192 In stock
25mg USD 412  USD412 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.

In vitro: A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC50s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC50 values of 3, 7, 80, 120 and 100 nM.

In vivo: A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer.

Protocol (for reference only)
Cell Experiment
Cell lines bone marrow cells
Preparation method 5 × 104 bone marrow cells were cultured for 4 or 24 h with or without the BCL-XL inhibitor A-1331852 in a 96-well plate in 100 μl of medium. Plates were allowed to equilibrate at room temperature prior to adding 100 μl Caspase-9 Glo reagent
Concentrations 1 μM
Incubation time 4 or 24 h
Animal Experiment
Animal models SCID-bg mice
Formulation
Dosages 25 mg/kg
Administration orally
Chemical Information
Molecular Weight 658.81
Formula C38H38N6O3S
CAS Number 1430844-80-6
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Moncsek A, et al. Hepatology. Targeting senescent cholangiocytes and activated fibroblasts with B-cell lymphoma-extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2-/- ) mice.

[2] Delbridge AR, et al. Cell Death Dis. The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL.

Related Bcl-2 Products
ABBV-467 

ABBV-467 is a selective MCL-1 inhibitor (Ki: <0.01 nM).

WEHI-539 

WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.

(Rac)-Lisaftoclax

(Rac)-Lisaftoclax ((Rac)-APG-2575) is a Bcl-2 inhibitor that can be uesd for hematologic malignancy research.

BcI-2/BcI-xI ligand 1 

BcI-2/BcI-xI ligand 1 is a BcI-2/BcI-xI ligand, and can be used for synthesis of PROTAC BcI-2/BcI-xI Degrader-1.

AZD-5991 (S-enantiomer) 

AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991.

  Catalog
Abmole Inhibitor Catalog




Keywords: A-1331852 , A1331852 supplier, Bcl-2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.